We are excited to be hosting a Tribe Public Webinar Presentation and Q&A Event with Eric Dobmeier, President & Chief Executive Officer of Chinook Therapeutics (NASDAQ: KDNY) on Thursday, April 15th, 2021 (8:30 am pacific / 11.30 am eastern). His presentation is titled "Revolutionizing The Treatment of Kidney Disease."

Mr. Dobmeier previously was the President and CEO of Silverback Therapeutics, a Seattle-based biotechnology company in the immuno-oncology space. Prior to that, he spent more than 15 years at Seattle Genetics, most recently as Chief Operating Officer, where he oversaw business development, corporate communications, manufacturing, program/alliance management activities and corporate strategy initiatives. While at Seattle Genetics, Eric was also directly involved in raising more than $1.2 billion in equity capital, and led negotiation and completion of multiple corporate alliances with leading biotechnology and pharmaceutical companies. Earlier in his career, he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Eric has a J.D. from University of California, Berkeley School of Law and an undergraduate degree from Princeton University. He is also a director of Atara Biotherapeutics and Adaptive Biotechnologies.

Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases, a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $120 billion in annual costs.

We will have limited seats for this event as we have a nice group confirmed already, so please reply quickly.

Back to Events

We are excited to be hosting Tribe Public's Next Webinar Presentation and Q&A Event which will be held Wednesday, April 13 (8:30 am PT/ 11:30 am ET). Our events are approximately 30 minutes in duration.

Mr. Steve Shum, Chief Executive Officer in CEO of INVO Bioscience (NASDAQ: INVO) will deliver a presentation titled "Democratizing Infertility - A Severely Underserved Global Market." He will be also be available for a 5-10 minute Q&A session at the end of the presentation. Send Questions to email: research@tribepublic.com.

INVO Bioscience (NASDAQ: INVO) is a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Their solution, the INVO® Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience.

Their lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI).

Their mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care.

Back to Events

We are excited to be hosting a Tribe Public Webinar Presentation and Q&A Event with Eric Dobmeier, President & Chief Executive Officer of Chinook Therapeutics (NASDAQ: KDNY) on Tuesday, January 26th, 2021 (8:30 am pacific / 11.30 am eastern). His presentation is titled "ALIGNED in the Fight Against Kidney Diseases"

Mr. Dobmeier previously was the President and CEO of Silverback Therapeutics, a Seattle-based biotechnology company in the immuno-oncology space. Prior to that, he spent more than 15 years at Seattle Genetics, most recently as Chief Operating Officer, where he oversaw business development, corporate communications, manufacturing, program/alliance management activities and corporate strategy initiatives. While at Seattle Genetics, Eric was also directly involved in raising more than $1.2 billion in equity capital, and led negotiation and completion of multiple corporate alliances with leading biotechnology and pharmaceutical companies. Earlier in his career, he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Eric has a J.D. from University of California, Berkeley School of Law and an undergraduate degree from Princeton University. He is also a director of Atara Biotherapeutics and Adaptive Biotechnologies.

Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases, a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $120 billion in annual costs.

We will have limited seats for this event as we have a nice group confirmed already, so please reply quickly.

Back to Events